|
|
View Clinical Trial (Medical Research Study)
|
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery - NCT00281957-98112 (Clinical Trial 136634)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy136634.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Seattle |
|
State:
|
|
WA |
| Zip Code: |
|
98112 |
| Conditions: |
|
Melanoma (Skin) |
| Purpose: |
|
RATIONALE: Sorafenib, temsirolimus, and tipifarnib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Sorafenib and tipifarnib may also stop
the growth of tumor by blocking blood flow to the tumor. It is not yet known whether
sorafenib is more effective when given together with temsirolimus or tipifarnib in treating
patients with malignant melanoma.
PURPOSE: This randomized phase II trial is studying how well giving sorafenib together with
either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that
cannot be removed by surgery.
|
| Study summary: |
|
OBJECTIVES:
Primary
- Compare the response rate (confirmed and unconfirmed and complete and partial) in
patients with unresectable stage IV malignant melanoma treated with sorafenib in
combination with either temsirolimus or tipifarnib.
- Compare the 4-month progression-free survival rate of patients treated with these
regimens.
- Compare the safety and tolerability of these regimens, with an emphasis on long-term
side effects and toxic effects, in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
metastatic (M) stage (M1a/b vs M1c). Patients are randomized to 1 of 2 treatment arms.
- Arm I (reopened to accrual as of 8/15/2009): Patients receive oral sorafenib twice
daily on days 1-28 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
- Arm II (closed to accrual as of 8/15/2009): Patients receive oral sorafenib as in arm I
and oral tipifarnib twice daily on days 1-21.
In both arms, courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.
All patients undergo CT scan or MRI at baseline and in week 9.
After completion of study treatment, patients are followed periodically for up to 3 years.
PROJECTED ACCRUAL: A total of 110 patients will be accrued for this study. |
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Histologically confirmed malignant melanoma of cutaneous origin
- Patients with unknown primary allowed
- Stage IV disease
- Measurable disease by physical examination, CT scan, MRI or plain x-ray
- Unresectable disease
- Residual or recurrent disease after prior surgery for stage IV disease allowed
- Residual tumor at the site of incomplete resection may be included only as
nonmeasurable disease
- Must have serum lactate dehydrogenase (LDH) levels measured
- Must have tissue specimens available
- No history of brain metastases
- Negative brain CT scan or MRI within the past 42 days
PATIENT CHARACTERISTICS:
- Zubrod performance status 0-1
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- SGOT or SGPT ≤ 2.5 times ULN (5 times ULN if hepatic metastases)
- Creatinine ≤ 1.5 times ULN
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9.0 g/dL
- Fasting cholesterol ≤ 350 mg/dL (lipid-lowering agents allowed)
- Triglycerides ≤ 300 mg/dL (lipid-lowering agents allowed)
- No symptomatic sensory neuropathy ≥ grade 2
- No evidence of bleeding diathesis or coagulopathy
- No congestive heart failure
- No myocardial infarction within the past 2 months
- No New York Heart Association class III or IV heart disease
- No condition that impairs the ability to swallow pills (e.g., gastrointestinal tract
disease resulting in an inability to take oral medication, requirement for IV
alimentation, prior surgical procedure affecting absorption, or active peptic ulcer
disease)
- No known allergy to imidazoles (e.g. clotrimazole, ketoconazole, miconazole, or
econazole)
- No history of allergic reaction to compounds of similar chemical or biologic
composition as tipifarnib
- No hypertension with systolic blood pressure (BP) > 140 mm Hg or diastolic BP > 90 mm
Hg
- Patients with well-controlled hypertension allowed
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No uncontrolled diabetes
- No uncontrolled chronic renal or liver disease
- No active uncontrolled infection
- No other severe or uncontrolled medical disease
- No psychologic or medical condition that would preclude study treatment or compliance
- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer, adequately treated stage I or II cancer that is in
complete remission, or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 90 days since prior adjuvant therapy, including cytotoxic agents
- At least 28 days since prior radiotherapy
- At least 28 days since prior surgery to remove the tumor
- No prior systemic therapy for stage IV melanoma
- No prior therapy with agents targeting farnesyl transferase, the MAP kinase pathway,
or vascular endothelial growth factors (VEGF) or receptors (VEFGR), including drugs
such as sorafenib, temsirolimus, or tipifarnib
- Concurrent lipid-lowering agents allowed
- Not requiring full-dose anticoagulation for recent thrombotic event
- No concurrent highly active antiretroviral therapy (HAART) in HIV-positive patients
- No concurrent use of any of the following:
- Dilantin
- Carbamazepine
- Phenobarbital
- Rifampin
- Hypericum perforatum (St. John's wort)
- Ketoconazole
- Itraconazole
- Ritonavir
- Cyclosporine
- Phenytoin
- Grapefruit juice |
|
|
|
| Study is available at: |
|
Group Health Central Hospital
Seattle, WA 98112
United States
Primary Contact:
Clinical Trials Office - Group Health Central Hospital
Phone: 206-287-2900 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
November 3, 2009 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|